Retatrutide: what the evidence actually shows, as of September 2026

Retatrutide is an investigational triple agonist at the GLP-1, GIP and glucagon receptors, developed by Eli Lilly. It is not approved by the FDA or any other regulator. Its Phase 3 TRIUMPH programme has now reported: up to 30.3% average weight reduction at 104 weeks in TRIUMPH-1, 20.8% and 22.6% at 12 mg in TRIUMPH-2 and TRIUMPH-3, and up to 28.7% at 68 weeks in TRIUMPH-4. Lilly has said it intends to file for approval in the first quarter of 2027. Everything currently sold outside a clinical trial is unapproved material of unverified provenance.

By Better Baseline · Last updated 16 September 2026

This page exists because the honest answer about retatrutide is genuinely more interesting than the marketing, and almost nobody writes it down.

What it is

Retatrutide is a single peptide that activates three receptors at once: GLP-1, GIP, and glucagon. That third one is what makes it different from anything already approved.

• GLP-1 agonism slows gastric emptying and reduces appetite. This is the semaglutide mechanism.
• GIP agonism adds a second incretin pathway. Tirzepatide does GLP-1 and GIP, which is why it outperformed semaglutide head to head.
• Glucagon receptor agonism is the new part. Glucagon raises energy expenditure and drives hepatic fat mobilisation. It also raises blood glucose, which is why it only works in combination with the two incretin arms that pull glucose the other way.

The design bet is that the incretin activity offsets glucagon's glycaemic effect while keeping its metabolic-rate effect. Hence the informal nickname "GLP-3," which is not a real drug class and does not describe anything.

What the human trials actually reported

This is the part worth getting exact, because the numbers get inflated in retelling.

Two things to notice.

The headline number is the top dose at the longest timepoint. TRIUMPH-1's 30.3% is at 104 weeks, which is two years of continuous treatment under trial supervision. TRIUMPH-2 and TRIUMPH-3 at 12 mg came in around 21 to 23%. Both sets are real; quoting only the first one is how "retatrutide does 30%" became a thing people say.

Phase 3 programmes report efficacy first and the full safety picture later. Topline results are press releases. The peer-reviewed publications, the adverse event tables, and the discontinuation rates are what a clinician actually reads, and for most of these they are not out yet.

Regulatory status, precisely

Retatrutide is not approved anywhere. It is an investigational drug.

Alongside the July 2026 results, Lilly stated it plans to submit a Biologics License Application to the FDA in the first quarter of 2027, covering obesity and with supporting filings in obstructive sleep apnoea and knee osteoarthritis.

A filing is not an approval. FDA review of a BLA typically runs ten to twelve months from acceptance, and the agency can ask for more data, restrict the label, or decline. The earliest plausible approval is therefore somewhere in late 2027 or 2028, and that assumes nothing surfaces in the safety data.

Which means: as of today, every milligram of retatrutide in existence outside a Lilly clinical trial is unapproved. There is no legitimate commercial supply chain, because the compound has no approved form to supply.

What that means for material you can actually obtain

Retatrutide is a 39-plus residue peptide. Synthesising it correctly is not trivial, and the things that go wrong are not visible in the vial.

Purity and identity are different questions. A certificate reporting 99% purity by HPLC says one peak dominates the sample. It does not say the peak is retatrutide. Identity is established by mass spectrometry, and a COA without it has answered the easier question.

Deletion sequences are the specific failure mode. In solid-phase synthesis, a coupling step that fails at one residue produces a peptide missing that amino acid. It is nearly the right mass and it chromatographs close to the target, so it can pass a loose purity spec while being a different molecule with unknown behaviour.

The COA has to match the vial. A lot number on the certificate that does not appear on what you received describes some other batch.

None of that is solvable by the buyer. It is a reason to be precise about what a certificate does and does not establish, which is covered in more depth in our piece on reading a certificate of analysis and on third-party versus in-house testing.

What nobody knows yet

• Long-term safety beyond the trial windows. The longest reported timepoint is 104 weeks, in a supervised population with exclusion criteria.
• What happens on discontinuation. With approved GLP-1 drugs, most of the lost weight returns after stopping. There is no reason to assume retatrutide differs, and no published data either way.
• Lean mass outcomes. Weight is not fat. The proportion of the loss that is lean tissue is the question that matters most for anyone over forty, and it is under-reported across this entire drug class.
• How any of it applies to unsupervised use of material of unknown identity at self-selected quantities. That is not a gap in the literature; it is outside it entirely.

FAQ

Is retatrutide FDA approved?

No. It is an investigational drug in Phase 3. Eli Lilly has said it intends to file a Biologics License Application with the FDA in the first quarter of 2027. A filing is not an approval, and FDA review typically takes ten to twelve months after acceptance.

How much weight did people lose on retatrutide?

Up to 30.3% average reduction at 104 weeks in TRIUMPH-1, 20.8% and 22.6% at the 12 mg dose in TRIUMPH-2 and TRIUMPH-3, and up to 28.7% at 68 weeks in TRIUMPH-4. The highest figures are top doses at the longest timepoints.

What is the difference between retatrutide, tirzepatide and semaglutide?

Semaglutide targets GLP-1. Tirzepatide targets GLP-1 and GIP. Retatrutide targets GLP-1, GIP and glucagon. The glucagon arm is intended to raise energy expenditure and mobilise liver fat, offset by the two incretin arms.

Is retatrutide a GLP-3?

No. "GLP-3" is informal shorthand with no scientific meaning. There is no GLP-3 receptor and no GLP-3 drug class. Retatrutide is a triple receptor agonist.

When will retatrutide be available by prescription?

Not before the FDA completes review of a filing that has not yet been submitted. On Lilly's stated Q1 2027 filing intention and typical review timelines, late 2027 at the earliest, and only if the review goes cleanly.

Does weight come back after stopping retatrutide?

There is no published discontinuation data for retatrutide. In trials of approved GLP-1 receptor agonists, most lost weight is regained after stopping treatment.

What should a retatrutide certificate of analysis show?

The specific lot number matching the vial received, the test date, purity by HPLC with the chromatogram attached rather than only a summary figure, identity confirmed by mass spectrometry, and an itemised impurity profile. Purity without identity does not establish what the material is.

Sources

• Eli Lilly, TRIUMPH-1 topline results, 21 May 2026.
• Eli Lilly, TRIUMPH-2 and TRIUMPH-3 topline results, 23 July 2026, including stated intention to submit a Biologics License Application in Q1 2027.
• Eli Lilly, TRIUMPH-4 topline results, December 2025.
• TRANSCEND-T2D-1 readout, March 2026.
• Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity, a Phase 2 trial. New England Journal of Medicine, 2023.

This page describes published research. It is not medical advice, not a recommendation, and not a suggestion that anyone obtain or use any compound discussed. Retatrutide is not approved for human use in any country.

All articles